MG
TVTX icon

Marex Group’s Travere Therapeutics TVTX Stock Holding History

Marex Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$542K Buy
18,227
+11,543
+173% +$345K ﹤0.01% 604
2025
Q4 		$255K Buy
+6,684
New +$217K ﹤0.01% 760

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marex Group's TVTX Position: Q1 2026 in Review

Marex Group increased its Travere Therapeutics (TVTX) stake by 173% in Q1 2026, buying an estimated $345K and bringing the position to 18,227 shares worth $542K. The position accounts for ﹤0.01% of the portfolio, ranked #604.

Marex Group first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Marex Group held 18,227 shares of Travere Therapeutics worth $542K as of Q1 2026.
  • Marex Group bought 11,543 Travere Therapeutics shares in Q1 2026, an estimated $345K.
  • Travere Therapeutics made up ﹤0.01% of Marex Group's portfolio in Q1 2026, its #604 holding.
  • Marex Group first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.